Almazov Centre and the Russian Corporation of Nanotechnology (RUSNANO) have signed a Memorandum of Understanding (MoU) to implement high-tech developments in healthcare. The signing parties were Director General of Almazov Centre Evgeny Shlyakhto and Chairman of the Executive Board of RUSNANO Management Company Sergey Kulikov.
The ceremony took place on June 1, the opening day of the Saint Petersburg International Economic Forum, during the strategic session at Almazov Centre involving world experts. The session was organized with the support of the international consultancy firm SAMSONOWA & Partners.
The parties identified the following areas for collaboration: smart clinic solutions, gene therapy, innovative pharmaceuticals, biomedical cell products, «Home to Hospital» and «Hospital to Home» technologies.
“Almazov Centre is the only medical research facility in Russia that provides its own training for students in the specialist degree programme. Every year, up to 3,000 medical professionals take training at other levels, including postgraduate training. Almazov Centre is developing a scientific and educational medical and biological centre for gifted children and youth Solnechny. The Centre has a huge scientific and educational potential to create a pool of the most highly sought specialists for emergent industries.
In 2020, Almazov Centre together with the Institute of Experimental Medicine won the competition to establish a world-class research centre for technology and personalized medicine. Almazov Centre became the core facility for the WCRC for Personalized Medicine.
This is an excellent basis for developing research areas and teams. The goal of WCRC is to establish a biomedical R&D ecosystem that will develop and implement diagnostic and treatment technologies based on personalized medicine, including the assessment of genetic risks, methods of pharmacogenetics and pharmacogenomics, disease biomodelling, genome modification and the creation of drugs for gene therapy and biomedical cell products with the use of genome editing technologies to improve the quality of treatment and reduce mortality in various cardiovascular diseases, metabolic comorbidities, hematological malignancies and certain types of solid tumors, some infectious diseases, as well as in genetic diseases, including rare and understudied ones,” said Evgeny Shlyakhto, Director General of Almazov Centre.
Almazov Centre is one of the few medical research centres licensed to provide education. This opens up opportunities for effective interaction with the Fund for Infrastructure and Educational Programmes of the RUSNANO Group that has already supported more than 200 training courses for advanced training and retraining of specialists for high-tech enterprises, including in the field of medicine.
“Our Memorandum aims at using the high research potential of the national science to improve the quality of medical services. The most advanced high-tech developments should become available to the widest possible population. It is very important for RUSNANO to cooperate with Almazov Centre since it not only carries out a lot of research but also has gained a rich practice of treatment. I am confident that the Centre will become one of our core customers in the biomedical area,” emphasized Sergey Kulikov, Chairman of the Executive Board of RUSNANO Management Company.
